ECT2 Increases the stability of EGFR and Tumorigenicity by Inhibiting Grb2 Ubiquitination in Pancreatic Cancer

Junxiong Wang\textsuperscript{1,2,3}, Shuo Yang\textsuperscript{4}, Li Min\textsuperscript{1,2,3}, Shengtao Zhu\textsuperscript{1,2,3}, Shuilong Guo\textsuperscript{1,2,3} and Shutian Zhang\textsuperscript{1,2,3}\textsuperscript{*}

\textsuperscript{1} Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, Beijing, China, \textsuperscript{2} Beijing Key Laboratory for Precancerous Lesion of Digestive Diseases, Beijing, China, \textsuperscript{3} National Clinical Research Centre for Digestive Diseases, Beijing, China, \textsuperscript{4} Department of Laboratory Medicine, Peking University Third Hospital, Beijing, China

The poor prognosis of patients with pancreatic ductal adenocarcinoma (PDAC) is associated with the invasion and metastasis of tumor cells. Epithelial cell transforming 2 (ECT2) is a guanine nucleotide exchange factor (GEF) of the Rho family of GTPases. It has also been reported that upregulation of ECT2 in pancreatic cancer, but the role and mechanism of ECT2 have not been previously determined. We found that ECT2 was significantly elevated in PDAC tissues and cells, correlated with more advanced AJCC stage, distant metastases, and overall survival of patients with PDAC. Inhibition and overexpression tests showed that ECT2 promoted proliferation, migration and invasion \textit{in vitro}, and promoted tumor growth and metastasis \textit{in vivo}. We determined that ECT2 was involved in the post-translational regulation of Grb2. ECT2 inhibited the degradation of Grb2 through deubiquitination. Furthermore, knockdown of ECT2 downregulated EGFR levels by accelerating EGFR degradation. EGF stimulation facilitated the formation of ECT2-Grb2 complex. Overall, our findings indicated that ECT2 could be used as a promising new therapeutic candidate for PDAC.

Keywords: PDAC, ECT2, EGFR, Grb2, EMT, ubiquitination

INTRODUCTION

ECT2 is located on the human chromosome 3q26.1-q26.2. As a guanine nucleotide exchange factor (GEF) of the Rho family of GTPases (1), ECT2 protein plays an important role in cell division (2). Rho family GTPases are involved in a variety of tumor progression signaling pathways (3). It has also been reported that upregulation of ECT2 in prostate cancer (4) and colorectal cancer (5) promotes malignant progression and predicts poor prognosis. Moreover, high expression level of ECT2 was associated with poor overall survival for pancreatic cancer patients (6). However, the role and mechanism of ECT2 in pancreatic cancer still remain unknown.

Abbreviations: AJCC, American Joint Committee on Cancer; DAPI, 4',6-diamidino-2-phenylindole; ECT2, epithelial cell transforming 2; EGFR, epidermal growth factor receptor; EMT, epithelial mesenchymal transition; FBS, fetal bovine serum; GEF, guanine nucleotide exchange factor; IHC, immunohistochemistry; PDAC, pancreatic ductal adenocarcinoma; TCGA, The Cancer Genome Atlas; TMA, tissue microarray.
EGFR plays a critical role in the progression of pancreatic cancer, which is overexpressed in pancreatic cancer (7). The high expression of EGFR is closely related to the tumor metastasis and poor prognosis of patients with pancreatic cancer (7, 8). Under EGF stimulation, downstream signaling pathways activate and regulate cell proliferation, migration and survival (8). Growth factor receptor-bound protein 2 (Grb2) is an adaptor protein widely expressed in many cells by regulating the receptor tyrosine kinase (RTK) signaling pathway. Grb2 recognizes and binds phosphorylated EGFR through SH2 domain and two SH3 domains (9–11). Grb2 recruits the E3 ubiquitin ligase Cbl, resulting in ubiquitination of the EGFR and EGFR degradation. Interaction with the GTP-bound active form of Ras results in Raf kinase (RTK) signaling pathway. Grb2 recognizes and binds factor receptor-bound protein 2 (Grb2) is an adaptor protein regulating cell proliferation, migration and survival (8). Growth factor receptor-bound protein 2 (Grb2) is an adaptor protein regulating cell proliferation, migration and survival (8).

In the present study, we investigated the expression and clinical significance in PDAC cells and primary tumors. Furthermore, we found that ECT2 promoted proliferation, migration, and invasion in vitro and tumor metastasis in vivo by Ubiquitinating Grb2 protein. Knockdown of ECT2 decreased the EGFR and induced MET. EGF stimulation promotes the formation of ECT2-Grb2 complex. Our research reveals a previously unknown mechanism of ECT2 in the progression of PDAC, in which ECT2 up-regulates Grb2 expression, leading to tumor growth and metastasis.

**MATERIALS AND METHODS**

**Ethics Statement**

Our research is conducted in accordance with the Declaration of Helsinki and international standards. All patients obtained written informed consent for this study, and the research protocol and process have been approved by the clinical research ethics committee of Beijing Friendship Hospital, Capital Medical University.

**Data Sources and Bioinformatics**

Oncomine and The Cancer Genome Atlas (TCGA) were used for predictive bioinformatics data. In Oncomine database, we retrieved the "ECT2" and selected the different gene analysis (pancreatic cancer and normal) to obtain differential expression results. TCGA-PANAD-RNA-Seq dataset was downloaded from TCGA database, which included 18 PDAC tissues and four adjacent normal tissues (14).

**Cell Culture and Transfection**

Five pancreatic cancer cell lines (AsPC1, BxPC3, CAPAN, PAC1, and SW1990) and human pancreatic ductal epithelial cells hTERT-HPNE were purchased from the American Type Culture Collection (Manassas, VA). Cells for experiment were obtained from the original stock preserved in liquid nitrogen. All of the cancer cell lines were maintained in RPMI 1640 or DMEM Medium (Invitrogen) and supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 mg/ml streptomycin (Invitrogen, Shanghai, China) at 37°C with 5% CO2. Specially, HPNE cell was cultured as described (15).

Plasmid of pLKO.1-shECT2, pLKO.1-shGrb2, ECT2-Flag, Grb2-Flag, and Scramble clone vectors were purchased from GENECHEM (Shanghai, China). Lentivirus was prepared following the instructions. The cells were subcultured to 10% confluence in a medium containing puromycin (Sigma-Aldrich, St. Louis, MO, USA). Antibiotic-resistant clones were picked and passed in medium containing puromycin. The level of expression was assessed by Western blot assay.

**Western Blotting and Immunofluorescence**

Cell lystate was prepared in RIPA buffer with addition of protease inhibitor cocktail, phosphatase inhibitor cocktail, DTT (Dithiothreitol), and Benzonase (Sigma-Aldrich, St. Louis, MO, USA). Protein concentration was calculated by the BCA Protein Assay Kit (Thermo Scientific Pierce, UK). Western blotting was performed using a standard method.

Antibodies for ECT2,Grb2, EGFR, AKT, pAKT, E-cadhein, N-cadhein, and Vimentin were purchased from Cell Signaling Technology Inc. (Beverly, MA). Antibody against actin was purchased from Santa Cruz Biotechnology (Santa Cruz, CA).

For immunofluorescence, briefly, cells were seeded on coverslips in six-well plates and fixed with 4% paraformaldehyde (PFA) at room temperature for 10 min. After three PBS-T (PBS with 0.1% tween-20) washes, cells were blocked for 5% BSA in PBS-T, then with Image-iT FX Signal Enhancer Ready Reagent (Life Technologies). The slides were incubated with primary antibodies overnight at 4°C and then incubated with Alexa Fluor® 594 goat anti-rabbit or Alexa Fluor® 488 goat anti-mouse (Molecular Probes). The slides were counterstained with DAPI and imaged using the confocal laser-scanning microscope LSM510 Meta (Carl Zeiss).

**TMA and Immunohistochemistry**

The study included a total of 100 PDAC patients, 80 of whom had adjacent normal tissues. The operation was performed from September 2004 to December 2008, and the patient was followed up until October 2012 or died. The median follow-up time was 12 months (range 0.6–87 months). During the follow-up period, 71 patients died of PDAC. All operations were R0 resection. The age, gender, pathological grade, TNM staging (according to AJCC), family history, smoking history, drinking history and type II diabetes history were collected. There was no significant difference in baseline characteristics between PDAC patients and adjacent normal tissue (control group) patients (Supplementary Table 1).

Immunohistochemistry (IHC) for ECT2 and Grb2 protein expression in TMA was performed by standard methods. The tissue sections were deparaffinized and hydrated. 3% H2O2 was used to block the endogenous peroxidase activity. 0.01M citrate buffer (pH 6.0) and microwave heat induction were used for antigen retrieval. ECT2 staining was scored according to the percentage and intensity of positive cells. The staining intensity was scored in four levels: 0 (no staining), 1 (weak staining), 2 (medium staining) and 3 (strong staining).

**In Vitro Migration, Invasion, and Wound Healing Assays**

Migration and invasion assays were carried out in 24-well plates using Boyden chambers with an 8-mm pore size PET membrane (Falcon). Briefly, cells were transfected with ECT2 or Grb2 shRNA; Cells was counted and processed for transwell assay. After a night, each of non-invasive cells on the upper surface of the
Matrigel membrane was gently removed. The invasive cells were fixed with anhydrous methanol and stained with toluidine blue. Under an inverted optical microscope, the stained cells that have passed through the membrane surface were photographed and quantified in three randomly selected areas. Results were obtained from three independent experiments performed in duplicate.

The wound healing assay was done by using ECT2 shRNA or non-specific shRNA cells. Briefly, when cells were grown to confluent, we used the 100 μl tip to scratch in the middle of the well. After this, we took photos of different wound regions and the size of the wound was calculated by image-J software (NIH, USA) and the relative wound closure was analyzed.

Soft Agar Colony Formation Assay
The cells were seeded in six-well plates containing agar. Growth medium with 10% FBS was added to the top of the agar. The cell suspension was plated and cultured in a 37°C incubator for 14 days. Finally, the colonies were fixed with 4% PFA, stained with crystal violet and counted.

In Vivo Xenograft Model
The animals were kept in facilities approved by the Animal Protection Committee of Capital Medical University, and experiments are carried out in accordance with the animal experiment guidelines. Tumor cells were injected into the axilla to establish subcutaneous tumor formation, and tail vein injection was used to establish a lung metastasis model.

Nude mice (BALB/c-nu) were acclimatized for a week. Stably transfected ASPC-1 cells (5×10⁶) were resuspended in PBS and implanted into axilla of male BALB/c nude mice by subcutaneous injection. The difference between tumor sizes of shScramble- and shECT2-transfected groups (12 mice per group) was evaluated. After the mice were sacrificed, the tumor tissues were excised and the weight and volume were measured. Finally, samples were extracted for various tests.

AsPC-1 cells (1 × 10⁷/ml) suspended in 100μl FBS-free medium were injected into the tail veins of 10 nude mice. The mice were sacrificed after 6 weeks. The number of lung metastases was counted, and then HE staining.
**Immunoprecipitation**
The protein G Dynabeads were pre-washed and incubated with rabbit anti-ECT2, mouse anti-Grb2, or their rabbit or mouse IgG control antibodies in 5% BSA IP buffer for 6 h. And then the beads were washed with IP buffer five times on a magnet. ASPC-1 cells were grown to a density of 70%–90% in a 15 cm dish, and then lysed with IP buffer for 30 min on ice. Lysates were cleared by centrifugation. Add 2 mg of total protein to the beads and incubated at 4°C for 2 h. After that, the beads were washed six times. Finally, boil the protein on the beads with 1x protein SDS, and boil it on a heating block at 95°C for 10 min. Immunoprecipitates were analyzed using SDS-PAGE.

**Statistical Analysis**
Experimental data are presented as the mean ± standard deviation (SD). Statistical analyses were performed using analysis of a two-tailed Student’s t test or chi-square test with either GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA) or SPSS Statistics software (version 20.0, Chicago, Ill). Survival curves were calculated using the Kaplan-Meier method. Differences were considered statistically significant when P values were less than 0.05.

**RESULTS**

**High Expression of ECT2 Is Associated With More Aggressive Clinicopathological Features of PDAC Patients**
In order to clarify the function of ECT2 in pancreatic cancer, we first evaluated the expression of ECT2 in the pancreatic cancer datasets of Pei Pancreas. We found that the mean expression value of ECT2 was significantly increased in PDAC tissues compared with the adjacent normal tissues (Figure 1A). To identify the expression of ECT2 in pancreatic cancer, we have analyzed 40 pairs of PDAC and normal tissues adjacent to cancer. ECT2 expression was significantly upregulated in tumor samples compared to normal tissues (P<0.001; Figure 1B). The expression of ECT2 was further tested by IHC in the TMA containing 80 paired PDAC tissues (Figure 1C). The correlation of ECT2 enhancement with clinicopathological features of pancreatic cancer patients was then explored. Patients were divided into low-ECT2 group and high-ECT2 group. We revealed a positive association between ECT2 overexpression and advanced histological grade, advanced AJCC stage, tumor size, distant metastases, smoking and Type II diabetes (Table 1). However, no significant association was observed between ECT2 expression with gender, age or lymph node metastasis. We found that high ECT2 expression was correlated significantly with poorer survival (Figure 1D). In addition, Pearson’s correlation test in the TCGA_PAAD dataset showed that ECT2 was positively correlated with Ki-67 (r = 0.7939, p < 0.0001, n = 178) (Figure 1E).

**ECT2 Promoted PDAC Cells Colony and Proliferation In Vitro**
PANC-1, AsPC-1, and CAPAN-1 cell lines were chosen for further investigation because of their high or low expression of ECT2 (Figure 2A). To investigate whether ECT2 positively regulates cell colony and proliferation, we employed the shRNA targeting ECT2 in PANC-1, AsPC-1 cells and established stable overexpression of ECT2 in CAPAN-1 cell. The transfection efficiency was confirmed by qRT-PCR. Firstly, the colony of shECT2 transfection group was significantly less than that of NC group (Figure 2B). Simultaneously, CAPAN-1/ECT2 cells had significantly more colonies compared with their control cells (Figure 2C). These results were further confirmed by cell proliferation assay. Knockdown of ECT2 expression significantly attenuated the growth of PANC-1 and AsPC-1 cells (Figures 2D, E). Overexpression of ECT2 significantly promotes the growth of CAPAN-1 cells (Figure 2F), indicating that ECT2 promotes PDAC growth.

**Loss of ECT2 Inhibits Cell Migration, Invasion, and EMT In Vitro**
We further investigated the role of ECT2 in the progression of PDAC. ECT2 knockdown significantly inhibited migration and invasion of PDAC (p <0.001; Figure 3A). Overexpression of ECT2 can significantly enhance the migration and invasion of PDAC (p <0.001; Figure 3B). Moreover, the wound healing assay also showed that the migration ability of ECT2 knockdown cells was significantly reduced compared to normal cells.

| Characteristics       | Number | ECT2 expression | P value |
|-----------------------|--------|----------------|---------|
| Age(years)            |        |                |         |
| <60                   | 50     | 21             | 29      | 0.99   |
| ≥60                   | 50     | 24             | 26      |        |
| Gender                |        |                |         |
| Male                  | 62     | 31             | 31      | 0.22   |
| Female                | 38     | 14             | 28      |        |
| Pathology grade       |        |                |         |
| I–II                  | 78     | 27             | 51      | 0.007  |
| above II              | 22     | 15             | 7       |        |
| Vessel/nerve invasion |        |                |         |
| Yes                   | 43     | 19             | 24      | 1.00   |
| No                    | 57     | 26             | 31      |        |
| Tumor invasion depth  |        |                |         |
| T1,T2                 | 79     | 40             | 39      | 0.08   |
| T3,T4                 | 21     | 5              | 16      |        |
| Lymph node metastasis |        |                |         |
| N0                    | 58     | 26             | 32      | 0.97   |
| N1                    | 42     | 19             | 23      |        |
| Distant metastasis    |        |                |         |
| M0                    | 96     | 41             | 55      | 0.02   |
| M1                    | 4      | 4              | 0       |        |
| AJCC-stage            |        |                |         |
| I–II                  | 74     | 28             | 46      | 0.04   |
| above II              | 26     | 17             | 9       |        |
| Tumor size            |        |                |         |
| ≤5cm                  | 60     | 20             | 40      | 0.007  |
| >5cm                  | 40     | 25             | 15      |        |
| Smoking status         |        |                |         |
| Yes                   | 36     | 24             | 12      | 0.002  |
| No                    | 64     | 21             | 43      |        |
| Type II diabetes      |        |                |         |
| Yes                   | 32     | 23             | 9       | <0.001 |
| No                    | 68     | 22             | 46      |        |

Bold values indicate statistical differences.

Frontiers in Oncology | www.frontiersin.org February 2021 | Volume 10 | Article 589241
In addition, PANC-1 cells grew as a scattering distribution and, upon ECT2 knockdown, acquired a circular shape and compact colonies, suggesting Mesenchymal epithelial transformation phenomenon (Figure 3D).

ECT2 Exerts Its Malignant Activity via Influencing Grb2

We revealed that ECT2 promoted proliferation and metastasis in pancreatic cancer. On the mentha website, through "protein-protein interaction analysis and prediction", it was found that there is a protein interaction between ECT2 and Grb2 (Figure 4A). Further, we found that knockdown of ECT2 lead to inhibition of Grb2 and phosphorylation of Akt. Simultaneously E-cadherin increased, Vimentin and N-cadherin reduced (Figure 4B). It was suggested that ECT2 may regulate EMT via Grb2/Akt pathway. As shown in Figure 4C, in immunohistochemistry for ECT2 and Grb2 protein, ECT2 expression was also significantly positively correlated with Grb2 expression (p<0.01, n=100). Immunofluorescence showed that Grb2 was highly expressed in the negative control group, while it was significantly reduced in the shECT2 group (Figure 4D). Our results indicated that ECT2 might promote the proliferation and metastasis of PDAC cells by partially regulating Grb2.

ECT2 Interacts With Grb2 Leading to Its Deubiquitination

We found that Grb2 level was decreased in the shECT2 cells compared with NC. Co-IP analysis was used to verify the potential interaction between ECT2 and Grb2 in PANC-1 cells. Endogenous ECT2 was found to be associated with Grb2 and conversely endogenous Grb2 was found to be immunoprecipitated with ECT2 (Figure 5A). ECT2 interacting with Grb2 confirmed the specificity of their interaction. In addition, ubiquitination assay confirmed that the loss of ECT2 significantly increased the level of Grb2 ubiquitination, thereby protecting Grb2 from degradation.
The proteasome inhibitor cycloheximide (CHX) was used to block protein degradation, and the interaction between ECT2 and GRB2 led to GRB2 deubiquitination (Figure 5B).

Previously, it was reported that Grb2 can promote EGFR endocytosis and intracellular transport, thereby inhibiting EGFR degradation and leading to the termination of signal transduction (13). Therefore, we investigated whether ECT2 regulated EGFR by Grb2 in pancreatic cancer cells. To determine whether Grb2 is required for ECT2-mediated EGFR regulation, we measured Grb2 in PANC-1 cell silencing of ECT2. Downregulation of ECT2 resulted in reduction of EGFR and Grb2. Knockdown of Grb2 inhibited the expression of EGFR and the activation of downstream pathways. We detected that ECT2 silencing inhibited EGFR signaling pathway and downstream targets E-cadherin. Then this inhibitory effect was amplified when cells were pretreated with Grb2 loss (Figure 5C), indicating that the interaction between ECT2 and Grb2 leads to increased EGFR and promotes EMT of pancreatic cancer cells. Endogenous ECT2 interacts with Grb2, while EGF stimulation can promote the formation of ECT2-Grb2 complex (Figure 5D). Grb2 induced EGF receptor protein accumulation. When PANC-1 cells were pretreated with EGF in the presence of cycloheximide, we found the degradation of EGFR in the ECT2 knockdown group was significantly faster than that in the control group. ECT2 silencing significantly inhibited EGFR function, including inhibiting the increase of the key proteins in EGF/EGFR-ERK/Akt signaling (pAkt and pERK)(Figure 5E). We quantified the results of Western Blot in Figure 5F. It indicated that the ECT2 could regulate the degradation of EGFR and downstream signaling pathways.

ECT2 Promotes Cancer Progression Through Grb2

We further verified whether ECT2 regulates the process of PDAC in a Grb2-dependent manner. Grb2 was down-regulated in PDAC cells. The knockdown efficiency was verified by western blot (Figure 6A). Colony formation and CCK-8 assays showed that the reduction of Grb2 significantly inhibited tumor cell proliferation (Figures 6B, C). In addition, we rescued the expression of Grb2 in ECT2 silenced PDAC cells. Interestingly, the overexpression of Grb2 in ECT2 silenced PDAC cells. Interestingly, the overexpression of Grb2 can partially attenuate the inhibition of Akt activation and EMT marker vimentin mediated by ECT2 silence (Figure 6D). The restoration of Grb2 expression eliminated the inhibition of ECT2 depletion-induced
proliferation and invasion abilities (Figures 6E, F). Taken together, these findings indicated that ECT2 regulates the progress of PDAC upstream of Grb2.

**Inhibition of ECT2 Suppresses Tumor Growth and Metastasis in Vivo**

The roles of ECT2 in pancreatic cancer cells in vitro were further verified using in vivo mice models. ECT2-silenced AsPC-1 cells were subcutaneously injected into the nude mice. Compared with NC group, the ECT2-depleted group revealed significant reductions in tumor size (Figure 7A), tumor volume and weight (Figures 7B, C).

Western blotting showed that decreased levels of Vimentin, N-cadherin decreased and E-cadherin increased accompanied by inhibition of EGFR/Akt/ERK pathways in ECT2 knockdown group compared to the negative control groups (Figure 7D).

To explore the effects of ECT2 on lung metastasis of PDAC cells, ECT2-silenced AsPC-1 cells were injected in the tail vein of nude mice. The mice were sacrificed 6 weeks later. The lung tissue was H&E stained after consecutive section. The number of lung metastases was independently calculated and evaluated by two pathologists. As shown in Figure 7E, the rate of lung metastasis was lower in ECT2 knockdown group than in negative control groups. The data indicated that ECT2 depletion represses the growth and metastasis of pancreatic cancer cells in vivo.

**DISCUSSION**

ECT2 is reported to be upregulated in several types of cancer (16, 17). Chen J et al. (18) found that ECT2 activated Rho/ERK signal to promote early recurrence in human hepatocellular carcinoma. Wang Y et al. (19) found that PKC1 binded to ECT2 via Par6 to form a complex and activates the MEK-ERK signaling pathway in ovarian cancer. Justilien et al. (20) reported that ECT2 was required for lung tumorigenesis and that Rac1 and PKC1 mediated ECT2 phosphorylation to promote ribosomal RNA (rRNA) synthesis. The prognosis of PDAC remains dismal and our knowledge of the underlying cellular molecular pathways remains limited. In this study, our results demonstrated ECT2 was significantly overexpressed in PDAC tumors. In addition, it
was found that the up-regulation of ECT2 expression predicted a shorter overall survival time for PDAC patients. We further demonstrated that ECT2 played critical roles in the proliferation, migration and invasion of PDAC cells, and promotes the growth and metastasis of tumors *in vivo*.

The GEF ECT2 has multiple substrates, including Rac1, RhoA, and Cdc42 (21). Here, we demonstrate that ECT2 is a positive regulator of Grb2 in pancreatic cancer. Grb2 plays a key role in enhancing the malignant characteristics of cancer cells (22), and that ubiquitination of Grb2 is still elusive. We revealed the potential mechanism of Grb2 regulation mediated by ECT2. We found that Grb2 protein levels and its downstream signaling were suppressed by ECT2 knockdown. The loss of ECT2 accelerated the degradation of Grb2 protein. In addition, Grb2 ubiquitination was significantly increased due to ECT2 depletion. It has been previously reported that E6AP enhanced ECT2 ubiquitination and proteasome degradation (23). Interestingly, ECT2 can also affect the stability of E2F1 by regulating the expression of deubiquitinating enzyme PSMD14 (24). So the mechanism by which ECT2 regulates the ubiquitination of Grb2 remains to be further studied.

EGFR plays key roles in essential cellular functions, including proliferation and migration (13). Overexpression of EGFR occurs in >90% of pancreatic cancer and is associated with a poorer prognosis (25). EGFR signaling in pancreatic cancer promotes proliferation and invasion of pancreatic cancer by
regulating EMT (26). Genetic studies in mice indicate that the development of PDAC requires EGFR expression. In the presence of oncogenic K-RAS mutants, EGFR plays an important role in acinar to ductal metaplasia (27, 28). In line with PDAC models, a kinase inhibitor specific to EGFR can sensitize tumors to chemotherapy (gemcitabine) (29). Indeed, EGFR inhibitors have shown limited but reproducible responses in PDAC patients, leading to US Food and Drug Administration approval of erlotinib for treating PDAC (Moore et al., 2007). A study confirmed that the combination of EGFR inhibitors and K-RAS-related inhibitors was a more effective way to treat PDAC (30).

In this study, knockdown of ECT2 decreased EGFR expression and inhibited its downstream signaling pathway. EGFR overexpresses in tumor tissue for two main reasons, one is gene amplification, and the other is blocked protein degradation. The data presented here suggested that ECT2 may potentially affect multiple cellular processes that drive PDAC progression through EGFR levels. ECT2 may regulate the level of Grb2 ubiquitination, while Grb2 ubiquitination reduces EGFR degradation. It is possible that the effect of ECT2 on EGFR may be mediated by Grb2.

Through the analysis of clinical data, we found that the high expression of ECT2 was related to advanced histological grade, advanced AJCC stage, distant metastases, smoking and Type II diabetes. At the same time, we observed a positive correlation between ECT2 and Grb2 and a poor prognosis for patients with high ECT2–expressing tumors. Therefore, our clinical data confirmed that ECT2 could promote the progression and metastasis of pancreatic cancer.

In conclusion, we have confirmed that ECT2 plays a key role in the progression of pancreatic cancer. These findings have
important implications for the prognosis and treatment of PDAC. The expression level of ECT2 may represent a biomarker of EMT, which can predict invasiveness and metastasis. Drugs that inhibit the activity of ECT2 may block the downstream pathways of EGFR. This targeted therapy may be an effective method to inhibit Grb2. In summary, for the first time, we report the relation between ECT2 and Grb2 in pancreatic cancer metastasis. We demonstrate that high ECT2 expression in pancreatic cancer suppresses the ubiquitination of Grb2 and activates the EGFR signaling pathway to promote metastasis (Figure 8). Our findings highlight the ECT2-Grb2-EGFR axis as a potential target for therapeutic intervention in pancreatic cancer metastasis.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

ETHICS STATEMENT

The animal study was reviewed and approved by Ethics Committee of Beijing Friendship Hospital. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.
AUTHOR CONTRIBUTIONS

JW and SZhang conceived and contributed to design of the study. SY and LM performed the experiments. SZhu and SG analyzed and interpreted the data. JW and SZhang supervised and contributed to writing the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This research was supported by Capital Medical University Research and Development Fund (PYZ2017149, PYZ2018151), Digestive Medical Coordinated Development Center of Beijing Municipal Administration of Hospitals (XXT05). The funding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2020.589241/full#supplementary-material

REFERENCES

1. Cook DR, Rossman KL, Der CJ. Rho guanine nucleotide exchange factors: regulators of Rho GTPase activity in development and disease. Oncogene (2014) 33(31):4021–35. doi: 10.1038/onc.2013.362
2. Greer ER, Chao AT, Bejsovec A. Pebble/ECT2 RhoGEF negatively regulates the Wingless/Wnt signaling pathway. Development (2013) 140(24):4937–46. doi: 10.1242/dev.101303
3. Li H, Peyrollier K, Kilic G, Brakebusch C. Rho GTPases and cancer. Biofactors (2014) 40(2):226–35. doi: 10.1002/biof.1155
4. Guo Z, Chen X, Du T, Zhu D, Lai Y, Dong W, et al. Elevated levels of epithelial cell transforming sequence 2 predicts poor prognosis for prostate cancer. Med Oncol (2017) 34(1):13. doi: 10.1007/s12032-016-0872-3
5. Luo Y, Qin SL, Mu YF, Wang ZS, Zhong M, Bian ZQ. Elevated expression of ECT2 predicts unfavorable prognosis in patients with colorectal cancer. BioMed Pharmacother (2015) 73:135–9. doi: 10.1016/j.biopha.2015.06.007
6. Liu B, Yang H, Taher L, Denz A, Grützmann R, Pilarsky C, et al. Identification of Prognostic Biomarkers by Combined mRNA and miRNA Expression Microarray Analysis in Pancreatic Cancer. Transl Oncol (2018) 11(3):700–14. doi: 10.1016/j.tranon.2018.03.003
7. Valsecchi ME, McDonald M, Brody JR, Hyslop T, Freydin B, Yeo CJ, et al. Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma. Cancer (2012) 118(14):3484–93. doi: 10.1002/cncr.26661
8. Sheng W, Chen C, Dong M, Wang G, Zhou J, Song H, et al. Calreticulin promotes EGF-induced EMT in pancreatic cancer cells via Integrin/EGFR-
ECT2 Inhibits Grb2 Ubiquitination

ERK/MAPK signaling pathway. Cell Death Dis (2017) 8(10):e3147. doi: 10.1038/cddis.2017.547

9. Ijaz M, Wang F, Shahbaz M, Jiang W, Fathy AH, Nesa EU. The Role of Grb2 in Cancer and Peptides as Grb2 Antagonists. Protein Pept Lett (2018) 24 (12):1084–95. doi: 10.2174/092986552466117123213148

10. Chen D, Si W, Shen J, Du C, Lou W, Bao C, et al. miR-27b-3p inhibits proliferation and potentially reverses multi-chemoresistance by targeting CBLB/GRB2 in breast cancer cells. Cell Death Dis (2018) 9(2):188. doi: 10.1038/s41419-017-0211-4

11. Herr R, Halbach S, Heizmann M, Busch H, Boerries M, Brummer T. BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effectors Grb2 in colorectal cancer cell lines. Oncogene (2018) 37(12):1576–93. doi: 10.1038/s41388-017-0063-5

12. Lin CC, Melo FA, Ghosh R, Suen KM, Stagg LJ, Kirkpatrick J, et al. Inhibition of basal FGF receptor signaling by dimeric Grb2. Cell (2012) 149(7):1514–24. doi: 10.1016/j.cell.2012.04.033

13. Tomas A, Futter CE, Eden ER. EGF receptor trafficking: consequences for signaling and cancer. Trends Cell Biol (2014) 24(1):26–34. doi: 10.1016/j.tcb.2013.11.002

14. Cancer Genome Atlas Research, Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet (2013) 45:1113–20. doi: 10.1038/ng.2764

15. Nalls D, Tang SN, Rodova M, Srivastava RK, Shankar S. Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of basal FGF receptor signaling. PLoS One (2011) 6:e24099. doi: 10.1371/journal.pone.0024099

16. Stengel K, Zheng Y. Cdc42 in oncogenic transformation, invasion, and tumorigenesis. Cell Signal (2011) 23(9):1415–23. doi: 10.1016/j.cellsig.2011.04.001

17. Wu WJ, Tu S, Cerione RA. Activated Cdc42 sequesters c-Cbl and prevents EGF receptor degradation. Cell (2003) 114(6):715–25. doi: 10.1016/S0092-8674(03)00688-3

18. Chen J, Xia H, Zhang X, Karthik S, Pratav S, Li JJ, et al. ECT2 regulates the Rho/ERK signalling axis to promote early recurrence in human hepatocellular carcinoma. J Hepatol (2015) 62(6):1287–95. doi: 10.1016/j.jhep.2015.01.014

19. Wang Y, Hill KS, Fields AP. PKCα maintains a tumor-initiating cell phenotype that is required for ovarian tumorigenesis. Mol Cancer Res (2013) 11(12):1624–35. doi: 10.1158/1541-7786.MCR-13-0371-T

20. Justilien V, Ali SA, Jamieson L, Yin N, Cox AD, Der CJ, et al. Ect2-Dependent rRNA Synthesis Is Required for KRAS-TRP53-Driven Lung Adenocarcinoma. Cancer Cell (2017) 31(2):256–69. doi: 10.1016/j.ccell.2016.12.010

21. Tatsumoto T, Xie X, Blumenthal R, Okamoto I, Miki T. Human ECT2 is an exchange factor for Rho GTPases, phosphorylated in G2/M phases, and involved in cytokinesis. J Cell Biol (1997) 139:921–8. doi: 10.1083/jcb.147.5.921

22. Giubellino A, Burke TR Jr, Bottaro DP. Grb2 signaling in cell motility and cancer. Expert Opin Ther Targets (2008) 12(8):1021–33. doi: 10.1517/14728222.12.8.1021

23. Mansour M, Haupt S, Chan AL, Godde N, Rizzitelli A, Lioi S, et al. The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling. Cancer Res (2016) 76(14):4236–46. doi: 10.1158/0008-5472.CAN-15-1553

24. Zhi T, Jiang K, Xu X, Yu T, Zhou F, Wang Y, et al. ECT2/PTTG1 axis promotes the proliferation of glioma through stabilizing E2F1. Neuro Oncol (2019) 21(4):462–73. doi: 10.1093/neuonc/noy207

25. Ueda S, Ogata S, Tsuda H, Kawarabayashi N, Kimura M, Sugiyama Y, et al. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas (2004) 29(1):e1–e8. doi: 10.1097/00006676-200407000-00061

26. Sheng W, Shi X, Lin Y, Tang J, Jia C, Rao R, et al. Musashi2 promotes EGF-induced EMT in pancreatic cancer via ZEB1-ERK/MAPK signaling. J Exp Clin Cancer Res (2020) 39(1):16. doi: 10.1186/s13046-020-1521-4

27. Ardito CM, Gruner BM, Takeuchi KK, Lubeseder-Martellato C, Teichmann N, Mazur PK, et al. EGF receptor is required for KRAS-induced pancreatic tumor genesis. Cancer Cell (2012) 22(3):304–17. doi: 10.1016/j.ccr.2012.07.024

28. Navas C, Hernández-Porras I, Schulmacher AJ, Soldin M, Guerra C, Barbadic M. EGF receptor signaling is essential for normal oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell (2012) 22(3):316–20. doi: 10.1016/j.ccr.2012.08.001

29. Wang Y, Hu GF, Zhang QQ, Gao J, Liu JX, et al. Efficacy and safety of gemcitabine plus erlotinib in locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis. Drug Des Deliv Ther (2016) 10:1961–72. doi: 10.2147/DDDT.S95412

30. Blasco MT, Navas C, Martin-Serrano O, Graña-Castro O, Lechuga CG, Martín-Díez AN, et al. Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF. Cancer Cell (2019) 35(4):573–87. doi: 10.1016/j.ccell.2019.03.002

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Wang, Yang, Min, Zhu, Guo and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.